There are currently 76 active clinical trials seeking participants for Renal Cell Carcinoma research studies. The states with the highest number of trials for Renal Cell Carcinoma participants are California, Texas, New York and Florida.
Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome
NCT04792463
Recruiting
This research will have a significant impact on the overall management of those cancer patients and their family members who are at risk for hereditary cancer due to germline inactivation of BAP1. Our study will ultimately facilitate the development of novel screening, prevention and treatment strategies for these individuals with the syndrome. Because the vast majority of UM develop in pre-existing nevi, characterization of individuals at high risk for development of UM will allow closer screen... Read More
Gender:
All
Ages:
All
Trial Updated:
10/23/2023
Locations: The Ohio State University Wexner Medical Center, Columbus, Ohio
Conditions: Uveal Melanoma, Cutaneous Melanoma, BAP1 Gene Mutation, Renal Cell Carcinoma, Mesothelioma, Hepatocellular Carcinoma, Cholangiocarcinoma, Meningioma Atypical
Register for Updates
TFE Renal Cell Carcinoma: A Prospective Registry and Translational Research Initiative
NCT03630536
Recruiting
There are limited data regarding the biology and treatment of TFE Renal Cell Carcinoma (TFE RCC). This project provides the infrastructure for acquisition of biological specimens, imaging, and correlative clinical data to facilitate biology studies and characterization of TFE RCC. This registry will collect clinical, demographic, and pathological data, specimens (as available) and imaging from patients with TFE RCC, prospectively. Cases are identified through: Existing clinical and/or cancer re... Read More
Gender:
All
Ages:
All
Trial Updated:
01/16/2024
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: Renal Cell Carcinoma
Register for Updates
Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma
NCT04955743
Recruiting
This is a phase 2, Simon's 2-stage designed study with 2 cohorts of anti-PD-1/PD-L1 experienced patients with untreated brain metastases: 1) melanoma and 2) renal cell carcinoma (RCC).
Gender:
All
Ages:
18 years and above
Trial Updated:
06/20/2024
Locations: Yale University, New Haven, Connecticut
Conditions: Melanoma, Renal Cell Carcinoma, Brain Metastases, PD1/PD-L1 Experienced, Pembrolizumab, Lenvatinib, Metastatic Melanoma
Register for Updates
Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant Disorders
NCT00001238
Recruiting
We will investigate the clinical manifestations and molecular genetic defects of heritable urologic malignant disorders. Families with urologic malignancy with known or suspected genetic basis will be enrolled. Affected individuals or individuals suspected of having a germline urologic malignant disorder will undergo periodic clinical assessment and genetic analyses for the purpose of: 1) definition and characterization of phenotype, 2) determination of the natural history of the disorder, and 3... Read More
Gender:
All
Ages:
2 years and above
Trial Updated:
06/19/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Kidney Cancer, Urologic Malignant Disorders, Renal Cell Carcinoma, Clear Cell Renal Cancer, Familial Renal Cancer (FRC)
Register for Updates
Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies
NCT05783622
Recruiting
This study is a first-in-human (FIH), Phase 1/1b, open-label, multicenter dose escalation and dose expansion study to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary anti-tumor activity of JANX008 in adult subjects with advanced or metastatic carcinoma expressing EGFR.
Gender:
All
Ages:
Between 18 years and 100 years
Trial Updated:
06/12/2024
Locations: City of Hope Medical Center, Duarte, California +8 locations
Conditions: Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Colorectal Carcinoma
Register for Updates
A Study of Adjuvant V940 and Pembrolizumab in Renal Cell Carcinoma (V940-004)
NCT06307431
Recruiting
The primary objective of the study is to compare V940 plus pembrolizumab to placebo plus pembrolizumab with respect to disease-free survival (DFS) as assessed by the investigator. The primary hypothesis is that V940 plus pembrolizumab is superior to placebo plus pembrolizumab with respect to DFS.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/12/2024
Locations: Yale-New Haven Hospital-Yale Cancer Center ( Site 0102), New Haven, Connecticut +16 locations
Conditions: Renal Cell Carcinoma
Register for Updates
Collection of Blood, Bone Marrow, Tumor, or Tissue Samples From Patients With Cancer to Study Drug Resistance
NCT00026663
Recruiting
This study will examine blood, bone marrow, tumor and tissue samples from patients with cancer to study tumor resistance to chemotherapy (drug treatment). Many patients with cancer improve initially with chemotherapy, but then have a disease relapse, after which their tumor no longer responds to treatment. Other patients tumors are drug-resistant from the start. The study will look for "resistance factors"-substances in blood and tissues that render tumors resistant to chemotherapy. The findings... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/06/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Renal Cell Carcinoma, Lung Carcinoma, Cervical Carcinoma
Register for Updates
A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma
NCT05805501
Recruiting
This study will evaluate the efficacy, safety, and pharmacokinetics of tobemstomig (also known as RO7247669) in combination with axitinib alone or with tiragolumab (anti-TIGIT) and axitinib, as compared to pembrolizumab and axitinib in participants with previously untreated, unresectable locally advanced or metastatic clear-cell renal cell carcinoma (ccRCC).
Gender:
All
Ages:
18 years and above
Trial Updated:
06/06/2024
Locations: University of Alabama at Birmingham; Comprehensive Cancer Center, Birmingham, Alabama +61 locations
Conditions: Renal Cell Carcinoma
Register for Updates
89Zr-DFO-Atezolizumab ImmunoPET/CT in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma
NCT04006522
Recruiting
This is an exploratory clinical trial to assess the potential of 89Zr-DFO-Atezolizumab Positron Emission Tomography/Computed Tomography (PET/CT) scans in patients with locally advanced or metastatic renal cell carcinoma (RCC). This open label, nontherapeutic trial will test the correlation of 89Zr-DFO-Atezolizumab immunoPET/CT with programmed death-ligand 1 (PD-L1) expression and the response to immune checkpoint inhibitor therapy in patients with RCC. There will be two cohorts, one made up of p... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/05/2024
Locations: UT Southwestern Medical Center, Dallas, Texas
Conditions: Renal Cell Carcinoma
Register for Updates
A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors
NCT05293496
Recruiting
Study CP-MGC018-02 is a study of vobramitamab duocarmazine (MGC018) in combination with lorigerlimab (MGD019). The study is designed to characterize safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics, and preliminary antitumor activity. Participants with relapsed or refractory, unresectable, locally advanced or metastatic solid tumors including, but not limited to, metastatic castration-resistant prostate cancer (mCRPC), melanoma, pancreatic cancer, hepatocellular carc... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/05/2024
Locations: University of California, Los Angeles, Los Angeles, California +9 locations
Conditions: Advanced Solid Tumor, Castration-Resistant Prostatic Cancer, Malignant Melanoma, Pancreatic Ductal Carcinoma, Hepatocellular Cancer, Epithelial Ovarian Cancer, Renal Cell Carcinoma
Register for Updates
A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma
NCT06234605
Recruiting
This is a Phase 1b, open-label, multicenter, safety, tolerability and efficacy study of HC-7366 in combination with belzutifan (WELIREG™). This is a multipart study that consists of a HC-7366 monotherapy cohort, a combination dose escalation, and a combination dose expansion. Approximately 80 patients will be enrolled in this study (up to 20 patients will be enrolled into the HC-7366 monotherapy cohort, up to 30 patients into the combination dose escalation, and up to 30 patients into the combin... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/04/2024
Locations: University of California San Diego Moores Cancer Center, La Jolla, California +10 locations
Conditions: Renal Cell Carcinoma
Register for Updates
Fasting Mimicking Diet for Reducing Immune Related Adverse Events for Cancer Patients on Immune Checkpoint Inhibitors, FMD-ICI Trial
NCT06438588
Recruiting
This clinical trial assesses an effective and translatable care model to understand and reduce the adverse effects that cancer patients experience during their treatment therapies and thereby enhance their well-being and quality of life. Excessive immune activation can affect multiple organs with the most common adverse effects being skin rash, diarrhea, colitis, fatigue, hypothyroidism and anorexia. A restrictive calorie diet, mostly of fat and complex carbohydrates, will mimic fasting and incr... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/31/2024
Locations: Mayo Clinic in Florida, Jacksonville, Florida
Conditions: Lung Non-Small Cell Carcinoma, Lung Small Cell Carcinoma, Malignant Solid Neoplasm, Melanoma, Renal Cell Carcinoma, Urothelial Carcinoma
Register for Updates